At high doses of next-generation BET inhibitors, patients with insulin resistance and Type 2 diabetes might benefit from both increased insulin stores and increased β-cell capacity to oxidize FA, protecting the β-cell from excess nutrient-induced damage. Here, INS is linked to type 2 diabetes mellitus.